Investment
Features
FeesSafety
Academy
More
Pluang+

Health Catalyst appoints Tami Reller to board as it advances AI-driven healthcare growth.

Market News
14 Sep 2026
PRNewsWire
View Source
Bullish
Health Catalyst appoints Tami Reller to board as it advances AI-driven healthcare growth.

Health Catalyst has appointed Tami Reller to its board of directors, effective October 1, 2026, where she will serve as audit chair and join the compensation committee. This move supports the company's next growth phase under new CEO Simeon Kohl, focusing on AI-driven healthcare intelligence to improve health system outcomes. Reller brings extensive experience in healthcare and technology leadership, including roles at Microsoft and UnitedHealth Group, positioning her to help Health Catalyst deliver impactful technology solutions. The company aims to leverage its $2.8 billion in validated outcomes and 18 years of expertise to solve complex healthcare challenges.

More News

Coda Octopus beats Q3 earnings and revenue estimates with strong defense and acoustic sales.

Coda Octopus beats Q3 earnings and revenue estimates with strong defense and acoustic sales.

Coda Octopus Group reported Q3 earnings per share of $0.12 and revenue of $7.7 million, exceeding analyst expectations. The company's growth was driven by its defense engineering and acoustic businesses, which offset a decline in marine technology sa...

Company Fundamentals
Bullish
31 minutes ago
Baldwin Group to go private at $32.50/share amid downgrade and legal scrutiny

Baldwin Group to go private at $32.50/share amid downgrade and legal scrutiny

Baldwin Group is going private in a $7.7 billion all-cash deal led by Sequence Holdings and DFO Management, offering shareholders $32.50 per share, an 88% premium over the June 2026 price. The transaction will delist Baldwin from Nasdaq and is expect...

Market News
Bearish
1 hour ago
BTIG raises Cullinan Therapeutics price target to $40 after positive lung cancer trial results

BTIG raises Cullinan Therapeutics price target to $40 after positive lung cancer trial results

BTIG increased its price target for Cullinan Therapeutics to $40, reflecting a potential 93% upside from the current stock price of around $20.73. This upgrade follows successful Phase 3 trial results for zipalertinib, a treatment for non-small cell ...

Analyst Insights
Bullish
2 hours ago
Pacifica Silver appoints new CFO and director after AGM, advancing Claudia Project in Mexico.

Pacifica Silver appoints new CFO and director after AGM, advancing Claudia Project in Mexico.

Pacifica Silver Corp. held its annual general meeting where all resolutions were approved, including the re-election of directors and appointment of auditors. Following the meeting, Alan Tam resigned as CFO and director, with Israel Munoz appointed a...

Company Fundamentals
Neutral
4 hours ago
Constellium's earnings are less tied to aluminum prices than believed, prompting a rethink of its risk and value.

Constellium's earnings are less tied to aluminum prices than believed, prompting a rethink of its risk and value.

An analyst challenges the common view that Constellium is highly cyclical and overly dependent on aluminum prices. The article explains that Constellium's earnings drivers are more complex and not solely linked to commodity price swings, suggesting a...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App